Health & Environmental Research Online (HERO)


Print Feedback Export to File
2722293 
Journal Article 
Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria 
Monroe, EW; Bernstein, DI; Fox, RW; Grabiec, SV; Lutsky, BN; Et al 
1992 
1 
Arzneimittel-Forschung
ISSN: 0004-4172
EISSN: 1616-7066 
IPA/93/1030101 
Forsch 
REF 3 
1119-1121 
IPA COPYRIGHT: ASHP A randomized, double blind, multicenter study was conducted to compare the efficacy and safety of loratadine (Clarityn) with those of hydroxyzine in 203 patients with chronic idiopathic urticaria who received an oral capsule of 10 mg loratadine once daily, 25 mg hydroxyzine 3 times daily, or placebo for 4-12 wk. Loratadine and hydroxyzine were significantly more effective than placebo and clinically comparable to each other as measured by all efficacy evaluations at each visit. Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than that seen with hydroxyzine. It was concluded that loratadine is as effective as hydroxyzine for the treatment of chronic idiopathic urticaria and is better tolerated.